C-Rad and SeeTreat Forge Alliance to Advance Personalised Radiotherapy Workflows

C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an announcement.

C-Rad AB has entered into a partnership with Australian software company SeeTreat to integrate C-Rad’s Catalyst# HD surface-guided radiation therapy platform with SeeTreat’s ART.1 adaptive decision support software. The combined solution is intended to cover the full radiotherapy session, from patient setup and real-time motion monitoring to automated assessment of whether a treatment plan remains optimal at each fraction.

By linking these complementary technologies, the companies aim to deliver faster, safer, and more personalized radiotherapy workflows for clinics of all sizes and equipment types, from major cancer centers to resource-constrained community hospitals. The collaboration is positioned to enhance clinical decision-making in real time, support wider access to personalized radiotherapy, and potentially strengthen C-Rad’s role in advancing intelligent, patient-centric cancer care, with more concrete product developments to be detailed later in 2026.

More about C-Rad AB Class B

C-Rad AB is a Sweden-based medical technology company specializing in surface-guided imaging solutions for radiation therapy, designed to deliver highly accurate tumor dosing while minimizing exposure to healthy tissue. Using high-speed 3D cameras and augmented reality, its systems streamline patient setup and monitor motion without tattoos or added imaging dose, improving safety, comfort, and workflow efficiency in cancer treatment centers worldwide.

Average Trading Volume: 23,528

Technical Sentiment Signal: Buy

Current Market Cap: SEK1.14B

See more insights into CRAD.B stock on TipRanks’ Stock Analysis page.